{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-068668","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.656435+00:00","generated_at":"2026-05-16T00:08:29.068907+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Cardiff Oncology furnishes Feb 2026 corporate presentation; no material news","bullets":["Corporate slide presentation furnished as Exhibit 99.1 for investor meetings.","Presentation highlights onvansertib development pipeline and opportunity.","No financial results, guidance, or operational milestones disclosed.","Routine Regulation FD disclosure; no material changes to business."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-068668","json":"https://secwatch.observer/filing/0001193125-26-068668.json","markdown":"https://secwatch.observer/filing/0001193125-26-068668.md","text":"https://secwatch.observer/filing/0001193125-26-068668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526068668/0001193125-26-068668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526068668/crdf-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:08:29.068907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}